Search Results

Your search for Julia Cipriano, MS,Julia Cipriano, MS matches 152 pages

Showing 151 - 152

By Julia Cipriano, MS / June 2024

Advanced Neuroendocrine Tumors: Adding Lu-177 Dotatate to Standard First-Line Therapy

As reported in The Lancet by Simron Singh, MD, MPH, FRCPC, and colleagues, primary results of the international, multicenter, randomized phase III NETTER-2 study have shown significantly improved progression-free survival with the addition of the radioligand lutetium-177 dotatate (Lu-177 dotatate)...

By Julia Cipriano, MS / May 25, 2024 / 2024 NCCN Annual Conference

NCCN Clinical Practice Guidelines in Oncology: 2024 Updates

The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...

Sep

Today In Oncology

Search Results

Your search for Julia Cipriano, MS,Julia Cipriano, MS matches 152 pages

Advanced Neuroendocrine Tumors: Adding Lu-177 Dotatate to Standard First-Line Therapy

NCCN Clinical Practice Guidelines in Oncology: 2024 Updates

Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC

High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT

Extended-Interval Dosing of Tarlatamab Found Safe Effective in SCLC

Favorable Safety Profile Found for Subcutaneous Tarlatamab in ES-SCLC

Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer